Conference Proceedings
Ibrutinib Treatment in Waldenstrom's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE™ Study
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramon Garcia-Sanz, David MacDonald, Veronique Leblond, Beatrice Mahe, Charles Herbaux, Constantine S Tam, M Lia Palomba, Jeffrey V Matous, Chaim Shustik, Eftathios Kastritis, Steven P Treon, Chih-Jian Lih, Jianling Li, Zeena Salman, Thorsten Graef, Meletios A Dimopoulos
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract Background : Rituximab (RTX) is commonly used to treat Waldenström's macroglobulinemia (WM). Treatment options are limited for patients (pts) who fail rituximab therapy. Single-agent ibrutinib (ibr) is highly active in WM and is approved in the United States and Europe for WM. In the phase 3 iNNOVATE study, ibr plus RTX resulted in significantly longer PFS and higher response rates vs RTX alone, both among TN and previously treated pts with WM (Dimopoulos MA, et al. N Engl J Med. 2018). Previous reports from the open-label, single-agent substudy showed sustained responses and a manageable toxicity profile in RTX-refractory WM, with a median follow-up of 18.1 mo (Dimop..
View full abstract